Kevin S. Landau, MD

Articles by Kevin S. Landau, MD

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma

ByLudovic Saba, MD,Kevin S. Landau, MD,Silvia Bunting, MD,Chakra P. Chaulagain, MD

Published: October 17th 2023 | Updated: October 25th 2023

Investigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.

Latest Updated Articles

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma
Published: October 17th 2023 | Updated: October 25th 2023

Kevin S. Landau, MD

Articles by Kevin S. Landau, MD

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma

Latest Updated Articles

Trending on CancerNetwork

GLP-1 Receptor Agonists in Breast Cancer: 5 Key Clinical Takeaways

Dato-DXd/Durvalumab Shows Promising Outcomes in Advanced TNBC

Ultra-Hypofractionation Proves Feasible in Locally Advanced Breast Cancer

A 22-Year-Old Patient With Colorectal Cancer: The Nuances of Care

Why is the Incidence of Colorectal Cancer Rising in Young Patients?